The Cost of Conception

Last week, about 8,000 fertility researchers, embryologists, and clinicians filled the ExCeL centre in London for the 42nd annual meeting of the European Society of Human Reproduction and Embryology (ESHRE), the largest gathering in reproductive medicine. The headlines that came out of it were mostly what you would expect: embryo culture advances, new data on frozen transfers, studies on sperm and air pollution. But the finding with the biggest real-world stakes involved no microscope and no lab work. It was a health economics analysis, and its subject was the number most patients know better than any lab result: the bill.

Presented on the meeting's opening day and published in the journal Human Reproduction, the study analyzed fertility treatment registry, economic, and demographic data from 22 countries and regions, covering more than 95% of the world's assisted reproduction activity. The researchers set out to answer a deceptively simple question: what does it actually cost a typical household, in each place, to bring home one baby through IVF? The answer explained between 77% and 84% of the difference in how many people use fertility treatment from one country to the next. Not culture, not religion, not clinic quality. Price. This article walks through what they found, why the usual way we talk about IVF costs hides the real number, and what this means for Americans during a policy window that closes, not incidentally, this Monday.

Most conversations about IVF pricing revolve around the cost of a cycle. The London researchers threw that framing out, because patients do not buy cycles. They are trying to have a child, and most people need more than one attempt to get there. So the team built a metric they call cost-to-baby: the average per-cycle price (including medications, embryo transfer, and genetic testing where used) multiplied by the age-weighted number of cycles it typically takes to achieve a live birth. Then they did something even more useful. They expressed that figure as a percentage of each country's median after-tax household income, both before and after subsidies, insurance, and tax credits.

In other words: not “what does IVF cost,” but “what share of what a normal family actually earns would it take to have a baby this way.” It is hard to overstate how rare that patient's-eye framing is in health economics, and how clarifying it turns out to be.

The spread is enormous. Gross cost-to-baby varied more than twelve-fold, from 66% of median household income in Israel to 833% in much of Africa. After public funding and subsidies were factored in, the out-of-pocket range ran from 13% of household income in Israel to 825% in the least-supported regions. The United States sits among the least affordable places in the developed world to have a baby through IVF, despite performing more cycles than almost anyone.

Affordability tracked use with striking consistency. In countries where the gross figure stayed under 100% of household income and out-of-pocket costs stayed under 50%, fertility treatment became something close to routine care: 11.8% of all births in South Korea now come from assisted reproduction, 11.7% in Spain, 9.3% in Japan. Where cost-to-baby climbed to two or three times annual household income, in Brazil, India, and Southeast Asia, ART births collapsed to 0.2% to 0.4%. Given that the World Health Organization estimates 1 in 6 people globally will experience infertility, those low numbers do not reflect low need. They reflect priced-out patients.

The study's most hopeful finding is also its most mathematical. The relationship between cost and access follows a power law, not a straight line, which means cost reductions buy disproportionately large gains. The authors estimate that halving out-of-pocket costs was associated with a 2.67-fold increase in ART births, with the biggest jumps in exactly the places where the barriers are highest today.

“Our analysis is fundamentally patient-centric: it asks what a typical household actually earns and what they would actually have to spend to have a baby through ART. The 50% threshold isn't a theoretical construct; it's a grounded observation of what top-performing nations have achieved.”

Dr. Stephanie Kuku, lead author, presenting at ESHRE 2026

Dr. Kuku's policy prescription follows directly from the metric: insurance mandates and public funding need to cover multiple complete treatment cycles, not just one. Every country that funds treatment generously per attempt but caps support at a single cycle is, by this math, buying patients a lottery ticket rather than a realistic chance. The data are unambiguous, she told the meeting: countries funding multiple cycles achieve higher utilization. South Korea pairs funding with a 30% income tax credit for fertility treatment, and it now leads the world in the share of babies born through ART.

The timing of this study is almost uncomfortably good for American readers, because the United States is in the middle of its most active fertility-policy moment in decades. As of this year, 15 states plus Washington, D.C. have laws requiring IVF coverage, and 25 states have some form of fertility mandate, though self-funded employer plans, which cover more than half of insured workers, are exempt from all of them. In May, the federal government proposed a rule creating “excepted fertility benefits”: standalone fertility coverage employers could offer separately from major medical insurance, like dental or vision, with a lifetime maximum of $120,000 per participant. The government's own arithmetic behind that cap ($15,000 to $20,000 per cycle, times roughly 2.5 cycles per successful pregnancy) is, notably, cost-to-baby thinking.

Reaction from patient advocates has been split in ways worth understanding. ASRM's chief advocacy officer Sean Tipton acknowledged the rule “may increase access” while falling short of the administration's promise of IVF without cost. RESOLVE, the national infertility association, went further, warning in its formal comment that the rule could pressure states to narrow existing fertility mandates and could leave patients with coverage that looks generous but sits outside the consumer protections of regular health insurance. Viewed through the London study's lens, the open question is simple: will this policy actually lower what a typical American household spends to bring home a baby, or just reorganize who writes the checks?

Have an opinion? The clock is running. The proposed rule is open for public comment through July 13, 2026. Anyone, including patients, can submit a comment on the Federal Register. Regulators are required to read and consider them, and patient stories about real costs are exactly the evidence this docket is missing.

Behind every percentage in the London data is a household doing this arithmetic at a kitchen table. In one survey of American women who went through fertility treatment, 70% took on debt, and nearly half owed at least $10,000. Fertility-specific financing cards can carry retroactive interest near 30% if the promotional window lapses. Some patients simply leave: CBS News has documented a growing wave of Americans traveling abroad for treatment, including one man who found four rounds of IVF in Colombia for $11,000, against roughly $60,000 at home. And an estimated half of large U.S. employers now offer some IVF coverage, but many workers have no idea it exists.

None of this is a personal failure of budgeting. It is what the London researchers measured, expressed one family at a time: a system where the price of trying, not the biology of it, is the thing that decides.

1.     Do your own cost-to-baby math. Price plans across two or three cycles, not one. A clinic package that looks expensive per cycle but includes multiple attempts may beat a cheaper single cycle. Ask every clinic for multi-cycle and refund-program pricing in writing.

2.    If you’re in the U.S., Check your state, then check your plan type. RESOLVE's state-by-state coverage guide shows what your state mandates. Then ask HR one specific question: is our plan fully insured or self-funded? If it is self-funded, the mandate does not apply to you, and the benefits conversation runs through your employer instead.

3.    Ask HR what fertility benefits already exist. Given how many employers quietly added coverage, the highest-return phone call in fertility finance is often to your own benefits department.

4.    If you have a view on the federal rule, file it by Monday, July 13. A two-paragraph comment describing what treatment actually cost you is more useful to regulators than a thousand form letters.

5.    If you are comparing countries, compare completely. Travel, medications, time away from work, and follow-up care all belong in the math. (We take up exactly this question in this week's companion piece.)

Dr. Kuku's team was frank about what their analysis leaves out: underserved communities within wealthy countries, the people who never make it into a registry because they never got to start. That research is coming next. But the study already hands patients and policymakers something they have rarely had, a single number that makes the access problem measurable, comparable, and therefore fixable. Twelve-fold differences between countries are not laws of nature. They are policy choices, and the power-law math says even partial fixes pay off more than anyone assumed. The question the London data leaves behind is not whether affordability can be engineered. South Korea, Spain, and Israel have already shown it can. The question is how long the rest of the map takes to catch up.

ESHRE press release: Halving fertility treatment costs could more than double births : the primary source for the 22-country study, presented July 6, 2026 in London.

Federal Register: Excepted Fertility Benefits proposed rule : full text and the public comment portal, open through July 13, 2026.

RESOLVE: Insurance coverage by state : plain-language guide to what your state does and does not require.

ASRM: Evaluating the administration's initiative on IVF : the professional society's running assessment of federal IVF policy.

SHRM: Proposed rule nudges employers to offer fertility benefits : useful background if you are bringing this conversation to your HR department.